MoCD Type A is a rapidly progressive autosomal recessive inborn error of metabolism resulting in toxic sulfite levels causing neurologic sequelae
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
Collaboration supports multiple discovery efforts, including vaccines
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Dr. Rizo brings extensive industry leadership experience to Vividion, having held multiple senior executive roles during her career at both biotechnology and large pharmaceutical companies.
Bringing next-gen cannabinoid therapeutics to cancer patients
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Subscribe To Our Newsletter & Stay Updated
